Anadys' hepatitis C drug shows promise in midstage trial

12/17/2009 | Reuters

An experimental hepatitis C drug from Anadys Pharmaceuticals helped reduce the virus to an undetectable level in 56% of midstage-trial patients, compared with 20% of the placebo group, after four weeks of treatment. ANA598 was combined with pegylated interferon and ribavirin, a standard therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX